AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare/Biotechnology stocks are attracting investors from everywhere due to the longer life spans and ageing population. These are especially attractive to investors looking for explosive gains and are somewhat risk tolerant. Letâs look at three such stocks:
KAZIA THERAPEUTICS LIMITED (ASX:KZA) - The general and administrative expenditure of the company has been decreased by 40% to $5.6 million in FY2018 with majority coming in the second half. The loss for the consolidated entity after providing for income tax amounted to $6,039,242 as compared to 30 June 2017 loss of 10,670,377. The consolidated entity had total funds, comprising cash at bank and on hand as at 30 June 2018, of $2,956,182 and short-term deposits of $3,000,000. Total current assets at year-end stand at $9,259,615 and the company also holds listed securities with a market value at year end in excess of $4 million, which are readily convertible into cash. The earnings per share (EPS) of the company is at -0.125 AUD. The stock declined to $0.357 and has seen a performance change of -44.93% over the past 6 months.Â
BIOTRON LIMITED (ASX:BIT) â After 12 weeks of antiretroviral therapy and BIT225 in an HIV1 Phase 2 clinical trial and has been accepted for presentation at HIV DART and Emerging Viruses 2018 at the meeting to be held in Florida. Estimates by GBI Research indicate that the market for HBV drugs is expected to reach US$3.5 billion by 2021. Raising $1.4 million after costs, the company completed a capital raising by way of an underwritten renounceable rights issue, in the second half of the financial year in review. There were no changes in environmental or other legislative requirements during the year that have significantly impacted the results or operations of the company. The stock surged by 4.762% to $0.220 and has seen a performance change of a staggering 950.00% over the past 6 months.
VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX:VHT) Ââ With HY revenue from customers sitting at $2.3M which is an increase of 83% compared to HY2018. With expectations as set out in the capital raise in May 2018, the company costs have risen this HY entirely consistent, when the forecasted costs to rise as it pursues more aggressive growth, especially in the US, however, the overall loss has risen to $5.0M. Also, the company retain $20M in the bank as at the end of Q2. The Annual Recurring Revenue (ARR) as at the HY was $4.8M which is up by 35%. The cash and cash equivalents at the end of the period was of $2.247 million with zero debt representing a decent balance sheet. The stock declined by 4.93% to $1.350 but has seen a performance change of a staggering 98.60% over the past 6 months.
EBITDA/Sales comparison of KZA, BIT, VHT, Source: Thomson Reuters
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
